Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
A dynamic and rapidly changing drug market for seropositive rheumatoid arthritis (RA) reflects attempts made in response to such autoimmune disorder’s peculiarities. Seropositive RA is indicated by certain antibodies namely, anti-citrullinated protein antibodies and rheumatoid factor (RF), among other people with rheumatoid arthritis. This market has undergone significant transformations in recent times with a focus on improving treatment outcomes and enhancing overall quality of life for those suffering from it.
This entails the use of disease-modifying anti-rheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), and sometimes biologics or targeted synthetic DMARDs as part of a multidimensional approach towards managing seropositive RA. The advent of biologics has greatly transformed therapy options as patients who do not respond well to conventional treatments have more personalized choices available. Understanding the immunopathology underlying seropositive RA has gone deeper resulting in researchers exploring new therapeutic opportunities geared towards optimizing treatment strategies.
Seropositive RA market for drugs is characterized by an interactive competition between pharmaceutical companies seeking innovative therapies. These firms have invested heavily in research and development of new medications that can not only control symptoms but also modify disease course. Regulatory framework including expedited approval pathways for breakthrough therapies have seen introduction of new products into markets within short periods targeting sero-positiveRAdrugpatients.
Clinical studies shape future developments within the growing industry of sero-positive RA drug production. Safety trials are conducted to determine if particular treatments will be safe while efficacy trials try to ascertain whether they will work or not. In addition, patient involvement in these tests has been instrumental in advancing medical knowledge leading to access to additional therapeutic solutions.
Seropositive Rheumatoid Arthritis Drug Market Highlights:
Seropositive Rheumatoid Arthritis Drug Market Scenario:
The Seropositive Rheumatoid Arthritis Drug Market is expected to reach at 7.20% CAGR during the forecast period 2022-2030.Arthritis means inflammation in a joint. The inflammation is characterized by swelling, pain, and redness within the joint. This type of arthritis is known to cause chronic inflammatory disorder in the hands and feet.
There are two types of rheumatoid arthritis are seronegative rheumatoid arthritis and seropositive rheumatoid arthritis. Smoking and family history are considered as some of the major cause of rheumatoid arthritis.
The rising R&D of product pipeline along with the introduction of novel products are some of the major trends in this market. For instance, in February 2016, Pfizer received FDA approval for commercialization of XELJANZ XR (tofacitinib citrate) in the U.S. market. The company launched the product in Europe for the treatment of rheumatoid arthritis. In May 2017, Sanofi received FDA approval for Kevzara drug for its commercialization in the U.S. market. Kevzara is used in the treatment of active rheumatoid arthritis.
The seropositive rheumatoid arthritis drug market is expected to be driven by factors such as rising cigarette consumption, growing healthcare expenditure, increasing female population, and increasing obese population. However, the growth of this industry is hindered by increasing treatment costs and high cost associated with R&D. The seropositive rheumatoid arthritis drug market is rather concentrated with few pharmaceutical companies dominating the market through new drug approval.
The seropositive rheumatoid arthritis drug market is expected to grow at a CAGR of approximately 4.0% during the forecast period 2017-2023.
Intended Audience
- Seropositive Rheumatoid Arthritis Drug Suppliers
- Seropositive Rheumatoid Arthritis Drug Manufacturers
- Research and Development (R&D) Companies
- Medical Research Laboratories
- Academic Medical Institutes and Universities
Research Methodology
 
Sources: Annual reports, Press release, White paper, and Company presentation
Segmentation
The seropositive rheumatoid arthritis drug market is segmented on the basis of the drug class, drug, treatment and diagnosis, route of administration, application, and end user.
On the basis of the drug class, the seropositive rheumatoid arthritis drug market is segmented into Non-steroidal anti-inflammatory drug type (NSAID), Steroids, and Disease-modifying anti-rheumatic drug type (DMARDs) and biologic agents.
On the basis of the drug, the seropositive rheumatoid arthritis drug market is segmented into Humira (adalimumab), Enbrel (etanercept), Remicade (infliximab), Rituxan (rituximab), Actemra (tocilizumab), Orencia (abatacept), and others.
On the basis of the treatment, the seropositive rheumatoid arthritis drug market is segmented into synovectomy, tendon repair, joint fusion, and total joint replacement.
On the basis of the diagnosis, the seropositive rheumatoid arthritis drug market is segmented into C -reactive protein (CRP) Test, CCP, ESR (Erythrocyte Sedimentation Rate) Test and Synovial Fluid Analysis.
On the basis of the route of administration, the seropositive rheumatoid arthritis drug market is segmented into oral, subcutaneous, intravenous, and others.
On the basis of the application, the seropositive rheumatoid arthritis drug market is segmented into medicine, scientific research, and others.
On the basis of the end user, the seropositive rheumatoid arthritis drug market is segmented into hospital, diagnostic centers, ambulatory surgical centers, and others
Regional Analysis
The seropositive rheumatoid arthritis drug market is segmented into the Americas, Europe, Asia Pacific and the Middle East and Africa.
The Americas dominated the overall market in terms of revenue in 2016 owing to the growing prevalence of arthritis, and rising cases of inflammation in the U.S.
Europe is the second largest rheumatoid market in the globe. The U.K is a major contributor to the European market. As per the National Rheumatoid Arthritis Society (NRAS), it was estimated that approximately 690,000 people suffer from rheumatoid arthritis in the U.K. Moreover, the government bodies are undertaking initiatives for the spreading awareness regarding rheumatoid arthritis is influencing the market growth.
The Asia Pacific is expected to be the fastest growing region, which accounts for more than 60% of the global population. The region has the potential to provide great opportunities for researchers to analyze the pathogenesis, epidemiology, and the factors that influence various manufacturers for expansion and setting up their manufacturing unit in this region.
The Middle East & Africa region contribute the least share of the seropositive rheumatoid arthritis market owing to the low R&D activities, lack of awareness, and poor medical facilities.
Key Players
Some of key the players in the seropositive rheumatoid arthritis drug market are Abbott Laboratories (U.S.), Johnson & Johnson Limited (U.S.), Novartis AG (Switzerland), Pfizer, Inc. (U.S.), and Eli Lilly and Company (U.S.), AbbVie Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Amgen (U.S.), Vertex Pharmaceuticals Incorporated (U.S), Sanofi-Aventis (France), AstraZeneca (U.K), Cadila Healthcare Ltd. (India), GlaxoSmithKline Inc. (U.S.), Merck and Co. Inc. (U.S.), and others
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
